Kenneth Lawlor, DO
Rheumatology · Prescott, AZNPI 1902917289
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 450 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,917 and has fallen 77.7% since, to $649 in 2025.
Across 450 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Pfizer$1000
- AstraZeneca$484
- Mallinckrodt Hospital Products Inc.$483
- Johnson & Johnson$435
- plus $3K from 21 others
Across 16 payments — averaging $1769.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$20K
- GSK$8K
What the payments were for
- Food & beverage$8,426100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,662 |
| Amgen(2 entities) | 77 | $1,399 |
| Pfizer | 62 | $1,000 |
| AstraZeneca(2 entities) | 32 | $484 |
| Mallinckrodt Hospital Products Inc. | 20 | $483 |
| Johnson & Johnson | 23 | $435 |
| Novartis | 19 | $400 |
| UCB, Inc. | 19 | $383 |
| Sanofi | 13 | $313 |
| E.r. Squibb & Sons, L.L.C. | 17 | $312 |
| Mallinckrodt Enterprises LLC | 14 | $302 |
| Lilly USA, LLC | 12 | $245 |
| Genentech USA, Inc. | 14 | $233 |
| Radius Health, Inc. | 9 | $181 |
| GSK | 9 | $139 |
| Boehringer Ingelheim | 5 | $106 |
| Merck | 5 | $83 |
| Sobi, Inc | 2 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Bristol Myers Squibb | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $14 |
How this compares
$8,440 in reported general payments places this provider in the 60th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 56 | $387,365 |
| Enbrel SureclickEtanercept | 34 | $248,606 |
| OtezlaApremilast | 34 | $169,434 |
| Orencia ClickjectAbatacept | 22 | $119,975 |
| SimponiGolimumab | 12 | $84,695 |
| Hydroxychloroquine Sulfate | 422 | $17,283 |
| MethotrexateMethotrexate Sodium | 348 | $7,901 |
| Leflunomide | 111 | $6,975 |
| Mycophenolate Mofetil | 33 | $5,020 |
| Pilocarpine Hcl | 29 | $3,622 |
| Febuxostat | 17 | $1,960 |
| Prednisone | 309 | $1,931 |
| Sulfasalazine | 55 | $1,587 |
| Gabapentin | 56 | $771 |
| Allopurinol | 72 | $748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,399 | $169,43434 claims |
| Johnson & JohnsonSimponi | $435 | $84,69512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Prescott
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Joy SchechtmanPeoria$860K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
- Paul HowardScottsdale$124K
- Sherif NasefYuma$111K
- Michael MaricicTucson$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.